Fuji Pharma Co., Ltd. (4554.T)
JPY 1362.0
(0.74%)
JPY 1362.0
(0.74%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 44.15 Billion JPY | 11.13% |
| 2022 | 39.73 Billion JPY | 25.91% |
| 2021 | 31.55 Billion JPY | 43.44% |
| 2020 | 22 Billion JPY | 2.94% |
| 2019 | 21.37 Billion JPY | 20.29% |
| 2018 | 17.76 Billion JPY | 4.82% |
| 2017 | 16.95 Billion JPY | -10.41% |
| 2016 | 18.92 Billion JPY | 10.13% |
| 2015 | 17.18 Billion JPY | -16.12% |
| 2014 | 20.48 Billion JPY | 35.9% |
| 2013 | 15.07 Billion JPY | 60.81% |
| 2012 | 9.37 Billion JPY | 10.36% |
| 2011 | 8.49 Billion JPY | 23.25% |
| 2010 | 6.89 Billion JPY | 3.75% |
| 2009 | 6.64 Billion JPY | 23.37% |
| 2008 | 5.38 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 40.93 Billion JPY | -3.91% |
| 2024 Q1 | 42.6 Billion JPY | -3.52% |
| 2024 Q3 | 43.52 Billion JPY | 6.31% |
| 2023 Q2 | 44.35 Billion JPY | 4.92% |
| 2023 Q4 | 44.15 Billion JPY | 0.47% |
| 2023 FY | 44.15 Billion JPY | 11.13% |
| 2023 Q1 | 42.27 Billion JPY | 6.4% |
| 2023 Q3 | 43.95 Billion JPY | -0.91% |
| 2022 Q3 | 38.58 Billion JPY | 0.1% |
| 2022 Q1 | 30.34 Billion JPY | -3.85% |
| 2022 Q2 | 38.55 Billion JPY | 27.04% |
| 2022 FY | 39.73 Billion JPY | 25.91% |
| 2022 Q4 | 39.73 Billion JPY | 2.97% |
| 2021 Q3 | 28.96 Billion JPY | -3.45% |
| 2021 Q1 | 22.18 Billion JPY | 0.85% |
| 2021 FY | 31.55 Billion JPY | 43.44% |
| 2021 Q4 | 31.55 Billion JPY | 8.96% |
| 2021 Q2 | 29.99 Billion JPY | 35.2% |
| 2020 FY | 22 Billion JPY | 2.94% |
| 2020 Q2 | 18.9 Billion JPY | 0.5% |
| 2020 Q3 | 22.73 Billion JPY | 20.27% |
| 2020 Q1 | 18.8 Billion JPY | -12.01% |
| 2020 Q4 | 22 Billion JPY | -3.22% |
| 2019 Q2 | 22.26 Billion JPY | 36.07% |
| 2019 Q3 | 21.81 Billion JPY | -2.03% |
| 2019 Q4 | 21.37 Billion JPY | -2.0% |
| 2019 FY | 21.37 Billion JPY | 20.29% |
| 2019 Q1 | 16.36 Billion JPY | -7.93% |
| 2018 FY | 17.76 Billion JPY | 4.82% |
| 2018 Q4 | 17.76 Billion JPY | 6.92% |
| 2018 Q3 | 16.61 Billion JPY | 4.38% |
| 2018 Q2 | 15.92 Billion JPY | -8.21% |
| 2018 Q1 | 17.34 Billion JPY | 2.32% |
| 2017 Q2 | 16.27 Billion JPY | -10.44% |
| 2017 Q1 | 18.16 Billion JPY | -3.98% |
| 2017 FY | 16.95 Billion JPY | -10.41% |
| 2017 Q4 | 16.95 Billion JPY | -0.26% |
| 2017 Q3 | 16.99 Billion JPY | 4.46% |
| 2016 Q1 | 18.96 Billion JPY | 10.35% |
| 2016 FY | 18.92 Billion JPY | 10.13% |
| 2016 Q3 | 18.29 Billion JPY | -1.97% |
| 2016 Q4 | 18.92 Billion JPY | 3.43% |
| 2016 Q2 | 18.66 Billion JPY | -1.57% |
| 2015 Q3 | 17.7 Billion JPY | -6.34% |
| 2015 Q2 | 18.9 Billion JPY | 3.38% |
| 2015 Q1 | 18.28 Billion JPY | -10.72% |
| 2015 FY | 17.18 Billion JPY | -16.12% |
| 2015 Q4 | 17.18 Billion JPY | -2.98% |
| 2014 Q2 | 16.62 Billion JPY | 2.53% |
| 2014 Q1 | 16.21 Billion JPY | 7.6% |
| 2014 FY | 20.48 Billion JPY | 35.9% |
| 2014 Q3 | 17.03 Billion JPY | 2.47% |
| 2014 Q4 | 20.48 Billion JPY | 20.22% |
| 2013 FY | 15.07 Billion JPY | 60.81% |
| 2013 Q1 | 14.92 Billion JPY | 59.21% |
| 2013 Q4 | 15.07 Billion JPY | 5.86% |
| 2013 Q2 | 15.39 Billion JPY | 3.18% |
| 2013 Q3 | 14.23 Billion JPY | -7.52% |
| 2012 FY | 9.37 Billion JPY | 10.36% |
| 2012 Q4 | 9.37 Billion JPY | 3.74% |
| 2012 Q3 | 9.03 Billion JPY | 9.7% |
| 2012 Q2 | 8.23 Billion JPY | -0.33% |
| 2012 Q1 | 8.26 Billion JPY | -2.71% |
| 2011 FY | 8.49 Billion JPY | 23.25% |
| 2011 Q3 | 7.85 Billion JPY | 1.1% |
| 2011 Q1 | 7.64 Billion JPY | 10.98% |
| 2011 Q4 | 8.49 Billion JPY | 8.07% |
| 2011 Q2 | 7.77 Billion JPY | 1.64% |
| 2010 Q3 | 5.98 Billion JPY | -10.24% |
| 2010 Q1 | 5.8 Billion JPY | -12.53% |
| 2010 Q2 | 6.67 Billion JPY | 14.82% |
| 2010 FY | 6.89 Billion JPY | 3.75% |
| 2010 Q4 | 6.89 Billion JPY | 15.09% |
| 2009 Q2 | 5.22 Billion JPY | 5.72% |
| 2009 Q1 | 4.94 Billion JPY | 0.0% |
| 2009 Q4 | 6.64 Billion JPY | 0.0% |
| 2009 FY | 6.64 Billion JPY | 23.37% |
| 2008 FY | 5.38 Billion JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 24.98 Billion JPY | -76.717% |
| Takeda Pharmaceutical Company Limited | 7834.78 Billion JPY | 99.436% |
| Sumitomo Pharma Co., Ltd. | 751.37 Billion JPY | 94.123% |
| Shionogi & Co., Ltd. | 164.35 Billion JPY | 73.132% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.39 Billion JPY | -1200.686% |
| Nippon Shinyaku Co., Ltd. | 42.86 Billion JPY | -3.009% |
| Kaken Pharmaceutical Co., Ltd. | 27.86 Billion JPY | -58.466% |
| Eisai Co., Ltd. | 494.82 Billion JPY | 91.076% |
| Morishita Jintan Co., Ltd. | 5.04 Billion JPY | -776.151% |
| Hisamitsu Pharmaceutical Co., Inc. | 61.69 Billion JPY | 28.424% |
| Mochida Pharmaceutical Co., Ltd. | 30.83 Billion JPY | -43.221% |
| Fuso Pharmaceutical Industries,Ltd. | 39.79 Billion JPY | -10.966% |
| Nippon Chemiphar Co., Ltd. | 31.08 Billion JPY | -42.06% |
| Tsumura & Co. | 132.88 Billion JPY | 66.77% |
| Kissei Pharmaceutical Co., Ltd. | 39.79 Billion JPY | -10.975% |
| Torii Pharmaceutical Co., Ltd. | 13.29 Billion JPY | -232.09% |
| Towa Pharmaceutical Co., Ltd. | 274.75 Billion JPY | 83.928% |
| Zeria Pharmaceutical Co., Ltd. | 70.7 Billion JPY | 37.546% |
| KYORIN Holdings, Inc. | 46.89 Billion JPY | 5.832% |
| Taiko Pharmaceutical Co.,Ltd. | 7 Billion JPY | -530.558% |
| Daito Pharmaceutical Co.,Ltd. | 25.43 Billion JPY | -73.584% |
| SymBio Pharmaceuticals Limited | 8.14 Billion JPY | -442.339% |
| MedRx Co., Ltd | 129 Million JPY | -34131.008% |
| Mizuho Medy Co.,Ltd. | 3.27 Billion JPY | -1249.351% |
| Solasia Pharma K.K. | 673 Million JPY | -6461.367% |
| Modalis Therapeutics Corporation | 645.5 Million JPY | -6740.867% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 31.38 Billion JPY | -40.716% |
| Sawai Group Holdings Co., Ltd. | 163.99 Billion JPY | 73.073% |
| Cyfuse Biomedical K.K. | 1.01 Billion JPY | -4266.286% |
| Toho Holdings Co., Ltd. | 523.98 Billion JPY | 91.573% |
| Koa Shoji Holdings Co.,Ltd. | 6.95 Billion JPY | -535.153% |